Ring Carbon Is Shared By Three Of The Cyclos Patents (Class 514/288)
  • Publication number: 20100196463
    Abstract: The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.
    Type: Application
    Filed: August 4, 2009
    Publication date: August 5, 2010
    Inventors: Maryka Quik, Donato Di Monte, J. William Langston
  • Publication number: 20100189698
    Abstract: A method for the treatment and/or prophylaxis of a neurological and/or neuropsychiatric disorder associated with altered dopamine function comprising administering to the eye of a patient in need thereof an effective amount of an agent that modulates neurotransmitter production or function.
    Type: Application
    Filed: June 30, 2008
    Publication date: July 29, 2010
    Applicant: CLARENCEW PTY LTD
    Inventor: Gregory Lynn Willis
  • Publication number: 20100172916
    Abstract: The present invention relates to new substituted hydroxyphenylamine based modulators of hormone and/or pigment levels, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: November 9, 2009
    Publication date: July 8, 2010
    Applicant: AUSPEX PHARMACEUTICALS, INC.
    Inventors: Thomas G. Gant, Craig Hodulik, Soon Woo
  • Publication number: 20100160295
    Abstract: Methods of preventing and/or treating at least one symptom of Restless Leg Syndrome (RLS) and its related disorders, including disorders such as periodic limb movements in sleep (PLMS) and periodic limb movement disorder (PLMD), are disclosed. The methods comprise identifying a host, afflicted with Restless Leg Syndrome (RLS) and its related disorders; and administering to the host a pharmaceutically effective amount of a 4-hydroxyphenylpyruvate dioxygenase. Also provided are methods and compositions for treating/preventing sleep disorders, and methods and compositions for improving sleep quantity and adequacy.
    Type: Application
    Filed: November 6, 2009
    Publication date: June 24, 2010
    Applicant: SYNOSIA THERAPEUTICS
    Inventors: Lesley PICKFORD, Uwe Meya, Mark Moran
  • Publication number: 20100158895
    Abstract: The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.
    Type: Application
    Filed: August 4, 2009
    Publication date: June 24, 2010
    Inventors: Maryka Quik, Donato Di Monte, J. William Langston
  • Publication number: 20100159004
    Abstract: The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.
    Type: Application
    Filed: August 4, 2009
    Publication date: June 24, 2010
    Inventors: Maryka Quik, Donato Di Monte, J. William Langston
  • Publication number: 20100152223
    Abstract: The present invention relates to a cabergoline crystal form L, its preparation from halogenated aromatic solvents and aliphatic hydrocarbons and to pharmaceutical compositions containing the new form.
    Type: Application
    Filed: January 30, 2008
    Publication date: June 17, 2010
    Applicant: LEK PHARMACEUTICALS D. D.
    Inventors: Zoran Ham, Andrej Premrl
  • Publication number: 20100151035
    Abstract: The present invention relates to a stable pharmaceutical composition of a poorly water-soluble drug with a view to increasing its solubility and bioavailability. The present invention relates to a solid dispersion of a poorly water-soluble drug.
    Type: Application
    Filed: March 10, 2008
    Publication date: June 17, 2010
    Applicant: Sandoz AG
    Inventors: Bharatrajan Ramaswami, Manisha Rajesh Patil, Aditi Das
  • Publication number: 20100151064
    Abstract: Described are compounds having a thiazolhydrazide scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said thiazolhydrazide compounds can be used for prophylaxis and/or treatment of neurodegenerative diseases and conditions.
    Type: Application
    Filed: November 5, 2007
    Publication date: June 17, 2010
    Inventors: Eckhard Mandelkow, Eva-Maria Mandelkow, Markus Pickhardt, Jacek Biernat, David George Lloyd, Boris Schmidt, Gregor Larbig
  • Publication number: 20100143475
    Abstract: The present invention relates to a transdermal therapeutic system (TTS) consisting of an impermeable coating, a matrix containing an ergoline compound having the formula (I) or a physiologically compatible salt or derivative thereof, wherein R1 denotes an H atom or a halogen atom and R2 is an alkyl group having 1 to 4 carbon atoms and denotes a single or double bond, and a removable protective layer, wherein the ergoline compound or a physiologically compatible salt or derivative thereof is stabilised by an antioxidant and a basic polymer.
    Type: Application
    Filed: August 27, 2007
    Publication date: June 10, 2010
    Inventors: Johannes Tack, Björn Schurad, Antje Müller-Schubert, Reinhard Horowski
  • Publication number: 20100137351
    Abstract: The present invention provides IA derivative compounds of the formula: where the variables are described herein.
    Type: Application
    Filed: September 10, 2009
    Publication date: June 3, 2010
    Applicant: Technion Research & Development Foundation Ltd.
    Inventors: Yehuda G. Assaraf, Eran E. Bram, Yamit Bney-Moshe, Andrzej M. Skladanowski
  • Patent number: 7713959
    Abstract: Disclosed are pharmaceutical compositions comprising mirtazapine and an anticonvulsant drug. Also disclosed are methods of preventing weight gain associated with the administration of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug. Further disclosed are methods of increasing the efficacy of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug.
    Type: Grant
    Filed: August 31, 2005
    Date of Patent: May 11, 2010
    Assignee: Duke University
    Inventors: K. Ranga R. Krishnan, Kishore M. Gadde
  • Publication number: 20100113499
    Abstract: The use of a dopamine agonist in the manufacture of a medicament for the treatment or prevention of endometriosis.
    Type: Application
    Filed: February 1, 2008
    Publication date: May 6, 2010
    Applicant: FERRING INTERNATIONAL CENTER S.A.
    Inventors: Antonio Pellicer-Martinez, Carlos Simon-Valles, Edurne Novella-Maestre
  • Patent number: 7705013
    Abstract: A method of treating trypanosomiasis in a mammal, which entails administering to a mammal in need thereof an effective amount of medicinal producting comprising a plant extract comprising one or more compounds of formula (I).
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: April 27, 2010
    Assignees: Institut de Recherche pour le Developpement, Universite Nationale d'Asuncion
    Inventors: Maria Elena Ferreira, Alain Fournet, Antonieta Rojas De Arias, Reynald Hocquemiller, Erwan Poupon
  • Publication number: 20100093706
    Abstract: The invention provides a class of inhibitors, packaged pharmaceuticals comprising such inhibitors, and uses of the inhibitors in treating, or the manufacturing medicaments for treating central nervous system disorders, including depression, anxiety, sleep disorders, obesity, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), sexual dysfunction, substance abuse, and movement disorders. Related business methods, such as methods for conducting a pharmaceutical business and methods for conducting a medical assistance reimbursement program, are also provided.
    Type: Application
    Filed: August 21, 2007
    Publication date: April 15, 2010
    Applicant: Prexa Pharmaceuticals, Inc.
    Inventor: James R. Hauske
  • Publication number: 20100069380
    Abstract: Provided herein are compounds that modulate the activity of a bacterial peptidyl tRNA hydrolase, including compositions and dosage forms comprising the compounds. Further provided herein are methods for screening and identifying compounds that modulate the activity of a bacterial peptidyl tRNA hydrolase. In particular, provided herein are assays for the identification of compounds that inhibit or reduce the activity of a bacterial peptidyl tRNA hydrolase. The methods provided herein provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads useful for preventing, treating, and managing a bacterial infection or one or more symptoms thereof. Further provided herein are methods for preventing or inhibiting bacterial proliferation as well as methods for preventing, treating, and/or managing a bacterial infection using such compounds and compositions.
    Type: Application
    Filed: September 21, 2007
    Publication date: March 18, 2010
    Inventors: Soongyu Choi, Arthur Branstrom, Scott A. Gothe, Richard Lipman, Tamil Arasu, Richard G. Wilde
  • Patent number: 7666877
    Abstract: Disclosed are ergoline derivatives, Formula (I), wherein either each of R1 and R2, independently, is H; optionally R10 and/or R11-substituted-phenyl or -phenyl-C1-4alkyl; optionally R10 and/or R11-substituted-heteroaryl or -heteroaryl-C1-4alkyl; optionally R10 and/or R11-substituted heteroaryl N-oxide; optionally R10-substituted C1-C8 alkyl; optionally R10-substituted C2-C8 alkenyl, optionally R10-substituted C2-C8 alkynyl; optionally R10-substituted C3-C8 cycloalkyl, or optionally R10-substituted C4-C8 cycloalkenyl; or R1 and R2 form together with the nitrogen atom to which they are attached an optionally R10-substituted 3-8 membered ring containing in addition to the nitrogen atom up to 2 heteroatoms selected independently from N, O and S; R3 is H; OR1; CH2R1R2; (CH2)1-2NR1R2; CH2—CH2—OR1; CH2—CO—NR1R2; or CO—CH2R1R2; R4 is F; Cl; Br; I; OR1; NR1R2 or has one of the significances given for R1; and R5 has one of the significances given for R1, in free form or in salt form for preventing or treating disorders
    Type: Grant
    Filed: May 29, 2006
    Date of Patent: February 23, 2010
    Assignee: Novartis AG
    Inventors: Rolf Baenteli, Fraser Glickman, Jiri Kovarik, Ian Lewis, Markus Streiff, Gebhard Thoma, Hans-Günter Zerwes
  • Publication number: 20100041690
    Abstract: Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D1 receptor agonist, and administering to the patient an effective amount of a dopamine D2 receptor antagonist, Pharmaceutical compositions comprising a dopamine D1 receptor agonist and a dopamine D2 receptor antagonist are also described. The D1 dopamine receptor agonist and the D2 dopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions.
    Type: Application
    Filed: September 11, 2009
    Publication date: February 18, 2010
    Inventors: Prabhavathi B. Fernandes, Richard Bernard Mailman, David Earl Nichols, Robert Niel Postlethwait
  • Publication number: 20100029665
    Abstract: The present invention provides novel methods and compositions for the treatment and prevention of headaches, vascular headaches, migraine headaches, cluster headaches, and migraine. One of the headaches, vascular headaches, migraine headaches, cluster headaches, and migraine treated by the methods and compositions of the invention is migraine.
    Type: Application
    Filed: April 8, 2009
    Publication date: February 4, 2010
    Inventors: Laurence R. Meyerson, Gregory T. Went, Timothy J. Fultz, Timothy S. Burkoth
  • Publication number: 20100016280
    Abstract: Activation of 5-HT2A receptors using agonists at surprisingly low concentrations was shown to potently inhibit TNF-?-induced inflammation in multiple cell types. Significantly, proinflammatory markers were also inhibited by the agonist, (R)-DOI, even many hours after treatment with TNF-?. With the exception of a few natural toxins, no current drugs or small molecule therapeutics demonstrate a comparable potency for any physiological effect. TNF-? and TNF-? receptor mediated inflammatory pathways have been strongly implicated in a number of diseases, including atherosclerosis, asthma, rheumatoid arthritis, psoriasis, type II diabetes, depression, schizophrenia, and Alzheimer's disease. Importantly, because (R)-DOI can significantly inhibit the effects of TNF-? many hours after the administration of TNF-?, potential therapies could be aimed not only at preventing inflammation, but also treating inflammatory injury that has already occurred or is ongoing.
    Type: Application
    Filed: July 10, 2009
    Publication date: January 21, 2010
    Inventors: Charles D. Nichols, Bangning Yu
  • Patent number: 7632843
    Abstract: The present invention belongs to the field of pharmaceutical industry and relates to a new method for the treatment of psychostimulant addiction, in particular cocaine addiction, or pharmaceutically acceptable acid addition salts thereof, with a therapeutically effective amount of 9,10-didehydro-N-methyl-N-(2-propy-nyl)-6-methyl-8?-aminomethylergo-line in the form of free base or in the form of pharmaceutically acceptable addition salt, in particular the bimaleate salt, as well as pharmaceutical compositions containing said compound. In literature, the compound is also known under code LEK-8829. More particularly, present invention relates to a novel method of treatment for reduction of abstinence symptoms after cocaine withdrawal and for suppression the symptoms of craving for cocaine withdrawal and for suppression the symptoms of craving for cocaine reinforcement, and to the use of said active substance for the preparation of the pharmaceutical composition for the treatment of cocaine addiction.
    Type: Grant
    Filed: December 11, 2003
    Date of Patent: December 15, 2009
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Igor Krisch, Marko Zivin, Natasa Milivojevic, Rudolf Rucman, Breda Bole-Vunduk, Uros Urleb
  • Publication number: 20090304816
    Abstract: A method of treating Restless Legs Syndrome (RLS) comprises the joint administration of an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent, in particular pramipexole, and iron in a biologically usable form, in pharmacologically effective combined amounts. Also disclosed is a corresponding use; a pharmaceutical composition comprising an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent, in particular pramipexole, and iron in a biologically usable form, and a pharmaceutically acceptable carrier; a package comprising a pharmaceutical composition for per-oral administration comprising an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent and a pharmaceutically acceptable carrier and a pharmaceutical composition for per-oral administration comprising iron in a biologically usable form and a pharmaceutical acceptable carrier.
    Type: Application
    Filed: December 6, 2006
    Publication date: December 10, 2009
    Applicant: CEREUSCIENCE AB
    Inventors: Ludger Grote, Jan Hedner, Kaj Stenlof
  • Patent number: 7622476
    Abstract: This invention relates to 1-allyl ergot alkaloids and their derivatives with selective antagonistic properties to 5-HT2 receptors for the prevention of, and relief from, migraine-related headache, Parkinson's disease, disorders of the thrombocyte function, etc.
    Type: Grant
    Filed: December 21, 2002
    Date of Patent: November 24, 2009
    Assignee: Axxonis Pharma AG
    Inventors: Miroslav Flieger, Heinz Pertz, Karel Kranda, Jan Cvak, Sven Jaenichen, Erika Glusa
  • Publication number: 20090285916
    Abstract: The invention provides a method for diagnosing a disorder or disease associated with an imbalance of monoamines in a subject, or of diagnosing susceptibility of the subject to the same, wherein the method comprising (a) providing a sample from a subject to be tested, (b) measuring the levels of dopamine, melatonin and/or serotonin in the sample; and (c) comparing the levels measured in step (b) with levels of dopamine, melatonin and/or serotonin associated with a reference population of subjects, wherein a difference in one or more of the levels measured in step (b) with the levels of dopamine, melatonin and serotonin associated with the reference population of subjects is indicative of a positive diagnosis. The invention further provides a method of prevention or treatment of a disorder or disease associated with an imbalance of monoamines, and kits for the same.
    Type: Application
    Filed: May 2, 2007
    Publication date: November 19, 2009
    Inventor: Susan Jane Alexia Haritou
  • Publication number: 20090275501
    Abstract: Disclosed is a series of somatostatin-dopamine chimeric analogs which retain both somatostatin and dopamine activity in vivo.
    Type: Application
    Filed: June 22, 2009
    Publication date: November 5, 2009
    Inventors: Michael D. Culler, Zheng Xin Dong, Sun H. Kim, Jacques-Pierre Moreau
  • Publication number: 20090264456
    Abstract: Compounds, e.g., of formula (I) and (Ia), pharmaceutical compositions comprising the compounds and methods of using the compounds and pharmaceutical compositions for treating pain disorders, e.g., disorders associated with cephalic pain, are provided.
    Type: Application
    Filed: March 20, 2009
    Publication date: October 22, 2009
    Inventor: Richard Andrew Sewell
  • Publication number: 20090232898
    Abstract: There is provided pharmaceutical compositions for the treatment of migraine comprising a pharmacologically-effective amount of a triptan or an ergot, or a pharmaceutically-acceptable salt thereof; a pharmacologically-effective amount of an antiemetic compound, or a pharmaceutically-acceptable salt thereof; a bioadhesion and/or a mucoadhesion promoting agent; and carrier particles, wherein the active ingredients are presented in particulate form upon the surfaces of the carrier particles, which carrier particles are larger in size than the particles of the active ingredients; and the bioadhesion and/or mucoadhesion promoting agent is, at least in part, presented on the surfaces of the carrier particles.
    Type: Application
    Filed: March 28, 2006
    Publication date: September 17, 2009
    Inventors: Anders Pettersson, Thomas Lundqvist
  • Publication number: 20090169601
    Abstract: A transdermal therapeutic system for administering lipophilic, poorly water-soluble and/or sparingly skin-permeable pharmaceutical active substances. The active substance is present in a multi-component enhancer system consisting of 4 components and each component of the multi-component enhancer system is selected from a different one of the substance groups: a) terpenes, b) cyclic glucitol ethers, c) medium-chain triglycerides of capric and caprylic acid and/or of linoleic acid; and d) longer-chain alcohols having a chain length of 8 or more carbon atoms.
    Type: Application
    Filed: October 4, 2006
    Publication date: July 2, 2009
    Applicant: LTS Lohmann Therapie-Systeme AG
    Inventors: Andreas Koch, Christoph Schmitz, Rolf Pracht, Mohammad Sameti
  • Patent number: 7531551
    Abstract: Provided are new crystalline Forms VIII, IX, XI, XII, XIV, XV, XVI, XVII, and XVIII of cabergoline. Also provided are novel processes for preparation of cabergoline Form I, Form II, Form VII, and amorphous cabergoline.
    Type: Grant
    Filed: May 7, 2004
    Date of Patent: May 12, 2009
    Assignee: IVAX Pharmaceuticals s.r.o.
    Inventors: Roman Bedná{hacek over (r)}, Ladislav Cvak, Alexandr Jegorov, Roman Sobotik
  • Publication number: 20090105632
    Abstract: An electrotransport system for delivery of lisuride or a pharmaceutically acceptable salt thereof. The system has a donor electrode assembly, a counter electrode assembly, and a controller electrically connected to the donor electrode assembly and the counter electrode assembly. The donor electrode assembly has a donor reservoir that contains a lisuride salt. The controller is electrically connected to the donor and counter electrode assemblies and is operatable for controlling current for the electrotransport.
    Type: Application
    Filed: October 7, 2008
    Publication date: April 23, 2009
    Inventors: Rama V. Padmanabhan, Joseph B. Phipps, Janardhanan Anand Subramony, Stephen S. Hwang
  • Publication number: 20090018127
    Abstract: Disclosed are ergoline derivatives, Formula (I), wherein either each of R1 and R2, independently, is H; optionally R10 and/or R11-substituted-phenyl or -phenyl-C1-4alkyl; optionally R10 and/or R11-substituted-heteroaryl or -heteroaryl-C1-4alkyl; optionally R10 and/or R11-substituted heteroaryl N-oxide; optionally R10-substituted C1-C8 alkyl; optionally R10-substituted C2-C8 alkenyl, optionally R10-substituted C2-C8 alkynyl; optionally R10-substituted C3-C8 cycloalkyl, or optionally R10-substituted C4-C8 cycloalkenyl; or R1 and R2 form together with the nitrogen atom to which they are attached an optionally R10-substituted 3-8 membered ring containing in addition to the nitrogen atom up to 2 heteroatoms selected independently from N, O and S; R3 is H; OR1; CH2R1R2; (CH2)1-2NR1R2; CH2—CH2—OR1; CH2—CO—NR1R2; or CO—CH2R1R2; R4 is F; Cl; Br; I; OR1; NR1R2 or has one of the significances given for R1; and R5 has one of the significances given for R1, in free form or in salt form for preventing or treating disorders
    Type: Application
    Filed: May 29, 2006
    Publication date: January 15, 2009
    Inventors: Rolf Baenteli, Fraser Glickman, Jiri Kovarik, Ian Lewis, Markus Streiff, Gebhard Thoma, Hans-Gunter Zerwes
  • Publication number: 20080311171
    Abstract: The present invention provides compositions, methods, and kits for treatment of Parkinson's disease and other conditions for which treatment with a dopamine agonist is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time. Dopamine agonist is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with dopamine agonist.
    Type: Application
    Filed: May 12, 2008
    Publication date: December 18, 2008
    Inventors: Rajesh A. PATEL, Louis R. Bucalo, Lauren Costantini, Sofie Kleppner
  • Publication number: 20080200453
    Abstract: The present invention is directed to a method of simultaneously treating hypertension, hypertriglyceridemia, a pro-inflammatory state, a pro-coagulative state, and insulin resistance (with or without treating obesity or endothelial dysfunction), associated with or independent from Metabolic Syndrome, as well as vascular disease such as cardiovascular, cerebrovascular, or peripheral vascular disease comprising the step of administering to a patient suffering from such disorders a therapeutically effective amount of a central acting dopamine agonist. In one embodiment, the central acting dopamine agonist is bromocriptine, optionally combined with a pharmaceutically acceptable carrier.
    Type: Application
    Filed: March 20, 2008
    Publication date: August 21, 2008
    Inventor: Anthony H. Cincotta
  • Publication number: 20080194522
    Abstract: The present invention relates to compounds useful for detecting the activity of monoamine oxidases, compounds useful for competitively inhibiting monoamine oxidases, for determining inhibitors of monoamine oxidases and compounds useful for treating monoamine oxidase-related nervous system pathologies, as well as pharmaceutical compositions and methods of manufacture thereof.
    Type: Application
    Filed: August 25, 2005
    Publication date: August 14, 2008
    Inventors: Gong Chen, Dominic J. Yee, Niko Gubernator
  • Publication number: 20080188510
    Abstract: The present invention relates to usefulness of zonisamide as a pharmaceutical composition for treating dementia or cognitive impairment.
    Type: Application
    Filed: May 23, 2006
    Publication date: August 7, 2008
    Applicant: Eisai R & D Management Co., Ltd.
    Inventor: Hiroshi Yoshino
  • Publication number: 20080166383
    Abstract: The present invention provides an antiallergic latex or PVC product, which includes one or more natural antiallergic medicines selected from baicalin, matrine, liquorice saponin, tea polyphenol, arctigenin, oleanolic acid, tetrandrine, sodium ferulate, total alkaloid of asiatic moonseed rhizome, extraction of cortex dictamni radics, ginkgo bilobal A, total glycoside of Rhizoma Anemones flaccidae, extraction of engelhardtia chryolepis, magnolin, osthole, catechin. The latex or PVC products of the present invention are generally in the forms of glove or condom. The present invention solves the problem of hypersensitivity to condom or glove in prior arts by adding the natural antiallergic medicine into the matrix of latex or PVC.
    Type: Application
    Filed: December 9, 2005
    Publication date: July 10, 2008
    Inventors: Zhengming Zhou, Yan Jiang
  • Publication number: 20070225312
    Abstract: The present invention relates to the use of terguride and proterguride for the prophylaxis and/or the treatment of chronic pain conditions as well as to pharmaceutical compositions comprising terguride and/or proterguride optionally together with an opiate analgesic.
    Type: Application
    Filed: March 21, 2007
    Publication date: September 27, 2007
    Applicant: ERGONEX PHARMA GMBH
    Inventors: GEORG LUDWIG, REINHARD HOROWSKI, HARALD BLIESATH, RUDOLF REITER
  • Publication number: 20070183982
    Abstract: Disclosed are new pharmaceutical formulations for aerosols with at least two or more active substances together with at least one surfactant for inhalative or nasal application.
    Type: Application
    Filed: January 29, 2007
    Publication date: August 9, 2007
    Inventors: Erhard Berkel, Hubert Hoelz, Friedrich Schmidt
  • Patent number: 7144843
    Abstract: An objective of the present invention is to provide a harmful organism control agent that possesses excellent control effect against harmful organisms and can be safely used. The present invention provides a compound of formula (1) or a salt thereof. The present invention also provides a harmful organism control agent comprising the compound of formula (1). wherein R1, n, R2, and R3 are as defined in the specification.
    Type: Grant
    Filed: January 31, 2002
    Date of Patent: December 5, 2006
    Assignee: Meiji Seika Kaisha, Ltd.
    Inventors: Kazuhiko Oyama, Takeshi Teraoka, Kazumi Yamamoto
  • Patent number: 7141582
    Abstract: Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance the activity of the enzyme. Preferred compounds for use in the method are imino sugars and related compounds. In particular, C8–12-alkyl derivatives of N-alkyl-deoxynojirimycin, isofagomine compounds, and calystegine compounds are effective to enhance glucocerebrosidase activity.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: November 28, 2006
    Assignee: Mount Sinai School of New York University
    Inventors: Jian-Qiang Fan, Satoshi Ishii, Naoki Asano
  • Patent number: 7081455
    Abstract: The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
    Type: Grant
    Filed: February 25, 2004
    Date of Patent: July 25, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Albert J. Robichaud, Taekyu Lee, Wei Deng, Ian S. Mitchell, Wenting Chen, Christopher D. McClung, Emilie J. Calvello, David M. Zawrotny
  • Patent number: 7071234
    Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3 antagonists.
    Type: Grant
    Filed: March 25, 2003
    Date of Patent: July 4, 2006
    Assignee: Sepracor Inc.
    Inventors: Thomas P Jerussi, Chrisantha H. Senanayake, Qun K. Fang
  • Patent number: 7026483
    Abstract: The invention provides methods for preparing amorphous physical form of cabergoline, and solvate form A of cabergoline useful in the preparation of the first mentioned physical form. A method for treating a prolactin disorder with medicaments prepared from amorphous physical form of cabergoline and solvate form A of cabergoline is also disclosed.
    Type: Grant
    Filed: April 20, 2004
    Date of Patent: April 11, 2006
    Assignee: Finetech Laboratories, Ltd.
    Inventors: Arie Gutman, Boris Tishin, Alex Vilenski, Albay Agazade, Boris Pertzikov, Gennady Nisnevich
  • Patent number: 6953854
    Abstract: A process for producing crystalline form I of cabergoline, which process comprises crystallization of the desired form from a toluene/diethyl ether mixture comprising raw cabergoline, followed by recovery and drying of the resulting crystals. A new solvate form V of cabergoline, useful as an intermediate, is also provided.
    Type: Grant
    Filed: October 31, 2003
    Date of Patent: October 11, 2005
    Assignee: Pharmacia
    Inventors: Attilio Tomasi, Stefania Magenes, Mario Ungari, Giuliano Ramella, Gianfranco Pallanza
  • Patent number: 6916829
    Abstract: Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance the activity of the enzyme. Preferred compounds for use in the method are imino sugars and related compounds. In particular, C8-12-alkyl derivatives of N-alkyl-deoxynojirimycin, isofagomine compounds, and calystegine compoiunds are effective to enhance glucocerebrosidase activity.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: July 12, 2005
    Assignee: Mount Sinai School of Medicine of New York University
    Inventors: Jian-Qiang Fan, Satoshi Ishii, Naoki Asano
  • Patent number: 6906040
    Abstract: Compositions and methods are provided for use in the treatment of cancer.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: June 14, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Giorgio Minotti, Luca Gianni
  • Patent number: 6849619
    Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6, R7, R8, R9, X, b, k, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: February 1, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Albert J. Robichaud, John M. Fevig, Ian S. Mitchell, Taekyu Lee, Wenting Chen, Joseph Cacciola
  • Patent number: 6844353
    Abstract: It has been found that sampangine and related analogs such as benzo[4,5]sampangine, 4-bromosampangine and 4-methoxysampangine may be used as effective fungicidal agents for plants. Fungicidal plant compositions and methods of using the materials for such a purpose are also provided.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: January 18, 2005
    Assignees: The United States of America as represented by the Secretary of Agriculture, The University of Mississippi
    Inventors: David E. Wedge, Dale G. Nagle
  • Patent number: 6838456
    Abstract: Compounds of the general structural formula and use of the compounds and salts and solvates thereof, as therapeutic agents.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: January 4, 2005
    Assignee: Lilly ICOS LLC
    Inventors: Mark W. Orme, Jason Scott Sawyer, Alain Claude-Marie Daugan, Françoise Gellibert, Romain Luc Marie Gosmini
  • Publication number: 20040241240
    Abstract: It is intended to provide external preparations for percutaneous application and compositions therefor whereby a hardly soluble drug such as a drug having an ergoline skeleton can be effectively absorbed via the skin into the blood under circulation while avoiding side effects on the digestive system observed in case of oral administration or side effects on the central system caused by a rapid increase in the concentration in the blood and a high adhesiveness to the skin can be established. This object can be established by composition characterized by containing a copolymer having N-vinyl-2-pyrrolidone as one of its constituents and percutaneous absorption preparations characterized by having a drug-containing adhesive layer containing such a composition and a support layer.
    Type: Application
    Filed: June 28, 2004
    Publication date: December 2, 2004
    Inventors: Takaaki Terahara, Kazunosuke Aida, Naruhito Higo, Shuji Sato